The Cancer Prevention and Control Program (CPCP) is a multidisciplinary effort to reduce overall and specific cancer incidence, mortality and morbidity in men and women across the age spectrum by conducting community-based interventional research. The major research areas are;1) primary prevention: identifying and implementing effective lifestyle (eg diet, exercise, weight control, smoking cessation), medical (eg chemoprevention, vaccines), and community interventions designed to prevent cancer development through dissemination and adoption of preventive strategies;2) secondary prevention;improving use of early detection programs and identifying and implementing optimal early diagnostic techniques;3) tertiary prevention: identifying and implementing effective lifestyle, medical and community interventions designed to improve the health and quality of life of persons living with or dying of cancer, and improving adherence to and effectiveness of treatments and quality of cancer care and management (eg emotional support, survivorship and quality of life of cancer patients, their families and caregivers). Cross-cutting these three areas is a focus on understanding and reducing the unequal burden of cancer in specific population groups. Plans for the next five years include: 1) tailoring current lifestyle interventions and assessment research to populations at greatest risk for specific types of cancer;2) expanding community health and health disparity research;3) enhancing intraprogrammatic collaborations among CPCP investigators to develop a cohesive research agenda;4) identifying translational opportunities and building strong inter-programmatic collaborations, particularly with investigators in Cancer Epidemiology (Program 09) and Immunology (Program 07), the latter of which may affect or be affected by the psychophysiology of cancer-related stress, and with the Shared Resources;5) strengthening the health policy research agenda for cancer prevention;and 6) enhancing and exploring current and new collaborations with cancer researchers at other institutions.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Ganjoo, Kristen; Hong, Fangxin; Horning, Sandra J et al. (2014) Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 55:768-72
Chiou, Shin-Heng; Kim-Kiselak, Caroline; Risca, Viviana I et al. (2014) A conditional system to specifically link disruption of protein-coding function with reporter expression in mice. Cell Rep 7:2078-86
Zhu, Gefei Alex; Danial, Christina; Liu, Andy et al. (2014) Overall and progression-free survival in metastatic basosquamous cancer: a case series. J Am Acad Dermatol 70:1145-6
Caswell, Deborah R; Chuang, Chen-Hua; Yang, Dian et al. (2014) Obligate progression precedes lung adenocarcinoma dissemination. Cancer Discov 4:781-9
Bartroff, Jay; Lai, Tze Leung; Narasimhan, Balasubramanian (2014) A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies. Stat Med 33:2718-35
Kohrt, Holbrook E; Thielens, Ariane; Marabelle, Aurelien et al. (2014) Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123:678-86
DiCarlo, Joseph; Agarwal-Hashmi, Rajni; Shah, Ami et al. (2014) Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 20:361-9
Chang, Serena; Kohrt, Holbrook; Maecker, Holden T (2014) Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother 63:713-9
Ansari, Celina; Tikhomirov, Grigory A; Hong, Su Hyun et al. (2014) Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small 10:566-75, 417
Lavori, Philip W; Dawson, Ree (2014) Introduction to dynamic treatment strategies and sequential multiple assignment randomization. Clin Trials 11:393-399

Showing the most recent 10 out of 24 publications